Recommended
More Related Content
What's hot
What's hot (15)
Viewers also liked
Viewers also liked (20)
Similar to Ourotech pitch deck
Similar to Ourotech pitch deck (20)
Recently uploaded
Recently uploaded (20)
Ourotech pitch deck
- 1. Ourotech Cancer treatment with certainty
- 2. 1st line treatment Herceptin combination 2nd line treatment T-DM1 3rd line treatment Xeloda 4th line treatment Hormone therapy Example: HER2+ Breast Cancer
- 3. Drug Resistance: Every cancer has a different weakness
- 4. The Problem Tumors can be resistant due to: - Genetic resistance/mutation - Tumor microenvironment - Interaction with other cancer cells - Interaction with healthy cells
- 5. The Solution Obtain patient tumor sample from biopsy Grow tumors in 96 well plate using proprietary hydrogel Test drug resistance of drugs/combinations Calculate human dosage Treat patient
- 6. Proof of Concept: IC50 Human IC50: 702nM Ourotech IC50: 600~650nM Alginate IC50: 200nM
- 8. $500/patient 1 hydrogel kit = 1 patient. Hydrogel is a consumable.
- 9. Market $7.05B $1.65B $204M 14.1M New Cancer Diagnoses/Year Worldwide 3.3M New Breast, Colorectal, Brain Cancer Diagnoses/Year Worldwide407K New Breast, Colorectal, Brain Cancer Diagnoses/Year in the US
- 10. Team Duleeka Ranatunga, CEO Prof Jonathan Blay Prof Shirley Tang William Lin, Head of R&D Christina Ryu, Business Development Ali Nikdel, R&DMichael Kim, Head of Finance
- 11. Funding Roadmap Strategic partnership with hospitals for preclinical trials Strategic partnership with big pharma client for clinical trials and distribution Start generating revenue by pharmaceutical drug testing services Optimize product based on drug testing and preclinical results Seed Series A
- 12. Funding and Milestones Ask: $1.5M Runway: 18 months Milestones
- 13. Traction 2 patents pending 2 academic pilots 2 pharma pilots, sales to start May 2017 1 Pre Clinical Trial In Progress Partnership for marketing
- 14. 2 Year Product Development Roadmap Humanized hydrogels Microfluidics and bioreactors Big data Machine learning algorithms Test immuno- therapies
- 16. Status Quo in Cancer Treatment Gene targets (+/-) Cancer subtype Other Variables Treatment plan
- 17. 0 10 20 30 40 50 60 70 80 90 100 1 10 100 1000 10000 100000 1000000 %viability Drug Concentration (nM) Doxorubicin (5 day exposure)
- 18. 0 10 20 30 40 50 60 70 80 90 100 1 10 100 1000 10000 100000 1000000 %viability Drug Concentration (nM) Doxorubicin (5 day exposure) 2% alginate 2% alginate + 1% HA Alginate IC50 = 200 nM Human IC50 = 702 nM Ourotech IC50 = 600 nM
- 19. Other Assays • Live/Dead • Trypan Blue staining • Western Blot • ELISA
- 22. • ~$10 000 per drug (10 dosage ATP assay) • 30-40% profit margins • Sales in 3-5 year contracts • Genentech, Novartis, big pharma Revenue model $3.5B $25.8 B Pharmaceuticals Clinics •In-house tests •Consumable supply •Stanford, Labcorp
- 23. Funding Breakdown ($1.5M) R&D New Hires Preclinical trials Marketing
Editor's Notes
- For the cancer cell culture, we have developed our first hydrogel product, Genesis, which is applicable to late-stage breast, colon, and brain cancer. We have 2 patents pending. And testing each drug or drug combo in 96-well plate format costs less than $10 worth of material.
- For current method of determining cancer treatment, first, the patient’s tumor will be screened for various cancer-related genes. Based on the presence of certain genes, the doctor will classify the patient into a cancer subtype. This piece of information is combined with other treatment variables such as cancer stage and past treatment records from other cancer patients to estimate what drug to use and at what dosage.
- After drug exposure, we use an ATP assay to determine tumor response. This is a plate-based assay that enables high-throughput screening. Here is an ATP assay curve showing breast cancer cell response to doxorubicin, which is a gold standard chemo drug. The IC50 value is defined as the drug concentration that kills or suppresses 50% of cells, and is used to determine if a drug is safe and effective.
- We have proven a higher than 90% cell viability with Genesis before drug exposure on multiple cell lines including HER2-positive breast cancer. Green circles are live cells and red ones are dead.
- For revenue generation in pharma space, sales are done according to industry standard and this gives us about $3,500 of profit for each drug tested. For clinics, the markup depends on whether they ship tumors to us for testing or we supply materials for them to do the testing. With pharma companies, we specify the number of drugs tested per year. Annual fee for up to a certain number of drugs
- We will be spending most of the money getting to clinical trials, growing sales, and expanding the team.